Patent Value Apportionment Rules for Complex, Multi-Patent Products

Abstract

Virtually all products now developed using biotechnology, genetic engineering, and chemistry are technology complex, incorporating many different inputs.While this alone complicates R&D efforts, there is also the added complexity of potentially relevant intellectual property (IP) rights held by third parties, attached to these inputs.For example, R&D for a new vaccine might have used numerous inputs with corresponding third-party proprietary rights attached: research tools, recombinant techniques, DNA sequences, transformation vectors, cell lines, adjuvants, and delivery services.").

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 19 citations exist upstream.